ALS drug trial ends early: what we learned about SPG302
NCT ID NCT06903286
First seen Jan 06, 2026 · Last updated May 18, 2026 · Updated 23 times
Summary
This study looked at the long-term safety of a daily oral drug called SPG302 in 16 people with ALS who had already taken part in an earlier study. The trial was stopped early, so results are limited. The main goal was to track side effects and changes in daily function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Flinders Medical Center
Adelaide, South Australia, 5042, Australia
-
Macquarie University
North Ryde, New South Wales, 2109, Australia
-
Royal Brisbane and Women's Hospital
Herston, Queensland, 4029, Australia
Conditions
Explore the condition pages connected to this study.